Safety and Completion Rate of Short‐Course Therapy for Treatment of Latent Tuberculosis Infection
Open Access
- 1 August 2006
- journal article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 43 (3) , 271-275
- https://doi.org/10.1086/505398
Abstract
Background. Nine months of isoniazid therapy is the recommended regimen for treatment of latent tuberculosis infection, but low completion rates areKeywords
This publication has 16 references indexed in Scilit:
- Severe or Fatal Liver Injury in 50 Patients in the United States Taking Rifampin and Pyrazinamide for Latent Tuberculosis InfectionClinical Infectious Diseases, 2006
- American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: Controlling Tuberculosis in the United StatesAmerican Journal of Respiratory and Critical Care Medicine, 2005
- National Survey to Measure Rates of Liver Injury, Hospitalization, and Death Associated with Rifampin and Pyrazinamide for Latent Tuberculosis InfectionClinical Infectious Diseases, 2005
- Adverse Events and Treatment Completion for Latent Tuberculosis in Jail Inmates and Homeless Persons*Chest, 2005
- Priorities for the Treatment of Latent Tuberculosis Infection in the United StatesNew England Journal of Medicine, 2004
- Use of Isoniazid for Latent Tuberculosis Infection in a Public Health ClinicAmerican Journal of Respiratory and Critical Care Medicine, 2003
- Pyrazinamide and Rifampin vs Isoniazid for the Treatment of Latent TuberculosisChest, 2003
- Short-Course Rifamycin and Pyrazinamide Treatment for Latent Tuberculosis Infection in Patients with HIV InfectionChest, 2002
- Targeted Tuberculin Testing and Treatment of Latent Tuberculosis InfectionAmerican Journal of Respiratory and Critical Care Medicine, 2000
- Adherence to Isoniazid Prophylaxis in the HomelessArchives of internal medicine (1960), 2000